about
The role of additional radiotherapy for primary central nervous system lymphomaThe role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaOcular and central nervous system lymphoma: clinical features and diagnosisPrimary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeClinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors.Advances in Primary Central Nervous System Lymphoma.Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma.High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.Biology and treatment of primary central nervous system lymphoma.Second-line treatment for primary central nervous system lymphoma.Radiation therapy for older patients with brain tumorsProgress in central nervous system lymphomas.High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaMolecular pathology of primary intraocular lymphoma.Pharmacotherapy of primary CNS lymphoma.R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Protocol for the use of polymerase chain reaction in the detection of intraocular large B-cell lymphoma in ocular samples.Intraocular lymphoma: update on diagnosis and management.Primary testicular and intraocular lymphomas: two case reports and a review of the literatureMultivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community.Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experienceThe utility of body FDG PET in staging primary central nervous system lymphomaNew approaches in primary central nervous system lymphoma.Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changesHow I treat CNS lymphomas.Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapyChemotherapy in newly diagnosed primary central nervous system lymphoma.Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.Cauda equina lymphoma--a rare presentation of primary central nervous system lymphoma: case report and literature review.Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities
P2860
Q24193995-475FE441-385A-479D-BE9F-27A899617A8BQ24236186-351CFF95-9BD0-40D1-9F22-2EE4637F3183Q27013785-0D1BC080-9827-4BC2-A6D8-49DED35336A7Q28206092-BD7D3092-5439-44B4-98D2-A1E5BEF69E0EQ30411362-4F9B4DD8-EFD5-490E-A93D-41D8F2F36B48Q30457046-A5242F30-91AA-40C7-84A2-45AA0AEA5BDFQ30581024-37F39CB6-E547-4E89-8690-8980B50D96E3Q31007237-4C6F967A-7446-489C-B98A-245CF92A747CQ31116141-0E6ABF08-3AD0-4235-98BF-4DB997E74E95Q31811481-E15CB6CD-6E5C-4FFA-B83C-8928C772F3B1Q31917410-8E558DF9-F841-44F5-930B-56ECE8DF7D3EQ33427514-CCAE8F64-B354-4986-A650-4C40DCBE85F1Q33475480-92DE4B5C-BB76-4620-9E76-3AE32240092DQ33535184-5A51017C-19B8-4921-8064-DF203A59D962Q33815025-B49171B0-D912-4E9C-AF14-6F0AC93A024EQ33934406-09A1A647-6A6B-4CE7-B8FA-0F706BD08E3FQ34132988-F2B0AD15-4536-4E70-923A-3B4CEBFA1A8AQ34331092-72E7B2E5-6CC3-4CBC-9F4F-03D2EEFCA023Q34482032-55CC7D73-8347-4164-AB72-D5D8F65B1264Q35126247-764E785C-4A6A-4C52-8517-06E26DFF536FQ35309325-EAE1F2A9-4CEC-455C-9AAD-0C0B1DF77DB9Q35639567-B163B15F-AC2E-4B62-8F20-3F720FE5930BQ35789568-2297CD1C-4DFE-4CF0-9FB3-497E53DD3C4AQ35892007-F320246B-0029-4FE6-803F-BDEC99C79753Q35908537-81693DF1-1A8C-4E4D-8553-DA5F30AD1051Q35976876-E801B925-4A68-4739-957C-D8BF18610D5CQ36492327-8F65E9FD-FD49-460F-B937-F958EFC2D1EEQ36684498-5F6B69B8-B198-42A1-94E6-D3F6D45EF831Q36694435-14E8BEEE-A03F-480A-9CA3-5E35BFD431DCQ36825376-E5223A37-E6EF-47CE-BFFA-E3EB47DCF88AQ37036944-73BB186E-E6AF-441D-9125-007FFCFF12DFQ37088471-295FEB0B-220D-46F7-A957-5B055F914869Q37137224-41850BB2-D349-4F02-AE08-8F10E4D897A8Q37215118-B88FA08B-05DA-46D6-9FC0-6B648E2B07BBQ37280734-F1E02FB7-8733-4FDC-B754-EB6FF69CEDCFQ37295494-9B827634-04A4-4C00-9E98-964D624A28BBQ37905596-9DD8B619-57C9-4C3B-961E-2136AEB8C6C1Q38005196-0693120C-8663-4764-AC69-A971F2A0E63BQ38024390-E4B2E384-13E7-41F1-A0DD-3EB346470872Q38055317-6925F0D5-89A6-4D26-9AA1-C547E5FE26D0
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Combined modality therapy for primary CNS lymphoma.
@en
Combined modality therapy for primary CNS lymphoma.
@nl
type
label
Combined modality therapy for primary CNS lymphoma.
@en
Combined modality therapy for primary CNS lymphoma.
@nl
prefLabel
Combined modality therapy for primary CNS lymphoma.
@en
Combined modality therapy for primary CNS lymphoma.
@nl
P2093
P1476
Combined modality therapy for primary CNS lymphoma.
@en
P2093
P304
P356
10.1200/JCO.1992.10.4.635
P407
P577
1992-04-01T00:00:00Z